Promising Results in Lung Cancer Trial with Pancreatic Cancer Drug

An early clinical trial revealed that one-third of patients with advanced lung cancer experienced tumor shrinkage. Larger trials are currently in progress to confirm these findings. The trial targeted individuals with advanced non-small-cell lung cancer who had previously undergone standard treatments, including chemotherapy.

According to clinical trial results published Wednesday in the New England Journal of Medicine, a drug initially developed for pancreatic cancer is showing promise against the most common form of lung cancer. This breakthrough offers potential new avenues for treatment in a patient population that has faced limited options.